These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

824 related articles for article (PubMed ID: 18925950)

  • 1. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
    Novelli F; Milella M; Melucci E; Di Benedetto A; Sperduti I; Perrone-Donnorso R; Perracchio L; Venturo I; Nisticò C; Fabi A; Buglioni S; Natali PG; Mottolese M
    Breast Cancer Res; 2008; 10(5):R74. PubMed ID: 18771580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
    Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
    Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
    Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
    J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 as a prognostic factor in breast cancer.
    Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
    Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer.
    Abdel-Fatah TM; McArdle SE; Johnson C; Moseley PM; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Br J Cancer; 2014 May; 110(10):2450-61. PubMed ID: 24755885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
    Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K
    J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S; Huang L; Chen CM; Shao ZM
    Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
    Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
    Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
    Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
    Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival analysis of breast cancer subtypes in patients with spinal metastases.
    Wang M; Jensen AB; Morgen SS; Wu CS; Sun M; Li H; Dahl B; Bünger CE
    Spine (Phila Pa 1976); 2014 Sep; 39(19):1620-7. PubMed ID: 24979144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
    Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
    J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
    Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
    Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.
    Dahl E; En-Nia A; Wiesmann F; Krings R; Djudjaj S; Breuer E; Fuchs T; Wild PJ; Hartmann A; Dunn SE; Mertens PR
    BMC Cancer; 2009 Nov; 9():410. PubMed ID: 19930682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.